NASDAQ:JANX Janux Therapeutics (JANX) Stock Price, News & Analysis $45.02 +0.85 (+1.92%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Janux Therapeutics Stock (NASDAQ:JANX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Janux Therapeutics alerts:Sign Up Key Stats Today's Range$43.44▼$45.4850-Day Range$35.29▼$50.2652-Week Range$5.65▼$65.60Volume412,782 shsAverage Volume719,433 shsMarket Capitalization$2.33 billionP/E RatioN/ADividend YieldN/APrice Target$66.13Consensus RatingModerate Buy Company OverviewJanux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Read More… War on Elon Escalates… (Ad)Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. Janux Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks70th Percentile Overall ScoreJANX MarketRank™: Janux Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 327th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingJanux Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageJanux Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Janux Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.18) to ($1.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Janux Therapeutics is -36.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Janux Therapeutics is -36.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJanux Therapeutics has a P/B Ratio of 6.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Janux Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.57% of the float of Janux Therapeutics has been sold short.Short Interest Ratio / Days to CoverJanux Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Janux Therapeutics has recently decreased by 0.30%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJanux Therapeutics does not currently pay a dividend.Dividend GrowthJanux Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.57% of the float of Janux Therapeutics has been sold short.Short Interest Ratio / Days to CoverJanux Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Janux Therapeutics has recently decreased by 0.30%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News Sentiment0.43 News SentimentJanux Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Janux Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for JANX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Janux Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,857,979.00 in company stock.Percentage Held by Insiders35.40% of the stock of Janux Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Janux Therapeutics' insider trading history. Receive JANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address JANX Stock News HeadlinesJanux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Ventures Xi L.P. Avalon Sells 958 SharesOctober 1, 2024 | insidertrades.comJanux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell Sells 25,000 SharesSeptember 28, 2024 | insidertrades.comEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.October 6, 2024 | Paradigm Press (Ad)Janux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Sells $7,427,457.00 in StockSeptember 15, 2024 | insidertrades.comJanux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Ventures Xi L.P. Avalon Sells 2,182 SharesSeptember 11, 2024 | insidertrades.comJanux Therapeutics (NASDAQ:JANX) Trading Up 3.5% - Time to Buy?October 5 at 10:58 AM | americanbankingnews.comJanux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Ventures Xi L.P. Avalon Sells 958 Shares of StockOctober 1, 2024 | americanbankingnews.comInsider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells 50,000 Shares of StockSeptember 28, 2024 | americanbankingnews.comSee More Headlines JANX Stock Analysis - Frequently Asked Questions How have JANX shares performed this year? Janux Therapeutics' stock was trading at $10.73 on January 1st, 2024. Since then, JANX stock has increased by 319.6% and is now trading at $45.02. View the best growth stocks for 2024 here. How were Janux Therapeutics' earnings last quarter? Janux Therapeutics, Inc. (NASDAQ:JANX) released its earnings results on Wednesday, August, 7th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.20. The firm's revenue was up 709.1% compared to the same quarter last year. When did Janux Therapeutics IPO? Janux Therapeutics (JANX) raised $152 million in an initial public offering (IPO) on Friday, June 11th 2021. The company issued 9,500,000 shares at $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager. Who are Janux Therapeutics' major shareholders? Top institutional investors of Janux Therapeutics include SG Americas Securities LLC (0.01%). Insiders that own company stock include Ra Capital Management, LP, Tighe Reardon, David Alan Campbell, Andrew Hollman Meyer and Ventures Xi LP Avalon. View institutional ownership trends. How do I buy shares of Janux Therapeutics? Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/07/2024Today10/06/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JANX CUSIPN/A CIK1817713 Webwww.januxrx.com Phone858-751-4493FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$66.13 High Stock Price Target$100.00 Low Stock Price Target$42.00 Potential Upside/Downside+46.9%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,290,000.00 Net Margins-291.17% Pretax Margin-291.17% Return on Equity-8.78% Return on Assets-8.20% Debt Debt-to-Equity RatioN/A Current Ratio57.34 Quick Ratio57.34 Sales & Book Value Annual Sales$15.13 million Price / Sales154.32 Cash FlowN/A Price / Cash FlowN/A Book Value$7.46 per share Price / Book6.03Miscellaneous Outstanding Shares51,851,000Free Float33,496,000Market Cap$2.33 billion OptionableOptionable Beta3.54 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:JANX) was last updated on 10/6/2024 by MarketBeat.com Staff From Our Partners⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.